Abstract：
There is growing interest in evaluating the safety and therapeutic potential of existing treatments such as tocilizumab (TCZ), an IL-6 receptor antagonist used to treat inflammatory diseases. However, there have been reports of increased inflammation in patients with HTLV-1 uveitis after TCZ treatment, and its ocular safety in the HTLV-1 infected state remains unknown. This study focused on assessing the impact of TCZ on HTLV-1-infected ocular cells using an in vitro model in which retinal pigment epithelial cells were cocultured with irradiated HTLV-1-infected T-cell lines. TCZ did not significantly affect cellular viability, inflammatory markers, or HTLV-1 proviral loads at various concentrations (25/50/100 µg/ml), indicating no increased risk of HTLV-1 viral infection and no exacerbation of the inflammatory aspects of HTLV-1 infection in the ocular cells. These promising results support the potential of TCZ as a safe treatment option for HTLV-1-infected patients, particularly those with eye infections.
摘要：
人们对评估现有治疗方法如托珠单抗（TCZ）的安全性和治疗潜力越来越感兴趣，用于治疗炎性疾病的IL-6受体拮抗剂。然而,有报道称TCZ治疗后HTLV-1葡萄膜炎患者的炎症增加，其在HTLV-1感染状态下的眼部安全性仍然未知。这项研究的重点是使用体外模型评估TCZ对HTLV-1感染的眼细胞的影响，其中视网膜色素上皮细胞与辐照的HTLV-1感染的T细胞系共培养。TCZ没有显著影响细胞活力，炎症标志物，或不同浓度的HTLV-1前病毒负荷（25/50/100µg/ml），表明HTLV-1病毒感染的风险没有增加，并且眼部细胞中HTLV-1感染的炎症方面没有恶化。这些有希望的结果支持TCZ作为HTLV-1感染患者的安全治疗选择的潜力。特别是那些眼睛感染的人。
